Organ Transplant Immunosuppressant Drugs Market Size, Share, And Growth Report 2032

Organ Transplant Immunosuppressant Drugs Market: Size

The global Organ Transplant Immunosuppressant Drugs Market size was worth around USD 5.40 billion in 2023 and is predicted to grow to around USD 7.17 billion by 2032 with a compound annual growth rate (CAGR) of roughly 3.2% between 2024 and 2032.

The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD billion). The report covers a forecast and an analysis of the Organ Transplant Immunosuppressant Drugs Market on a global and regional level.

Request Free Sample

Organ Transplant Immunosuppressant Drugs Market: Overview

Organ transplant refers to a medical procedure wherein a donor organ is transplanted into the body of a recipient to replace a missing or damaged organ. Autograft is a transplant type wherein organs or tissues are transplanted in the same person’s body. Allograft can be from a cadaveric or living source and refers to a transplant between two subjects of the same species. Organ transplantation is usually done no other treatment works or in case of end-state organ failures such as kidney, heart, or liver failure. The immune system may attack the newly transplanted organ if the donor and recipients are not matched. Transplant rejection is quite common and the person with a transplanted organ has to take immunosuppressant drugs for a lifetime.

The demand for the organ transplant immunosuppressant drugs market is driven by growing demand for transplantation, increasing investment in research and development in tissue engineering, and technological advancements in organ transplant. Increasing chronic disease burden is another factor that is contributing to the organ transplant immunosuppressant drugs market growth. However, the low availability of organs and high cost of overall transplantation procedures may hamper the market growth.

Global Organ Transplant Immunosuppressant Drugs Market Size: Segmentation

The study provides a crucial view on organ transplant immunosuppressant drugs by segmenting the market based on drug class, Transplant Type,  and region. All the segments of the organ transplant immunosuppressant drugs market have been analyzed based on present and future trends and the market is estimated from 2024 to 2032.

Based on drug class, the global organ transplant immunosuppressant drugs market is bifurcated into antibodies, steroids, mTOR inhibitors, antiproliferative agents, and calcineurin inhibitors. The calcineurin inhibitors drug class segment held the largest market share in 2023 whereas the antibodies segment is expected to exhibit the highest CAGR over the forecast period. Calcineurin inhibitors drug class includes majorly two drugs cyclosporine and tacrolimus. These effective drugs have widely been used for almost 20 years.

Based on transplant type, global organ transplant immunosuppressant drugs market is bifurcated into pancreas, lung, heart, liver, kidney, and others. The kidney transplant was the most common transplant type across the globe in 2023. This is attributed to the comparatively easy availability of donor organs compared to other organs. Also, a kidney transplant is more cost-effective compared to prolonged periods of dialysis.

Based on the distribution channel, global organ transplant immunosuppressant drugs market is segmented into retail pharmacies, online pharmacies, and hospital pharmacies. Hospital pharmacies held the leading market share in 2023 since it is the most widely preferred channel of distribution.

Organ Transplant Immunosuppressant Drugs Market: Report Scope

Global Lambda Cyhalothrin Market: Regional Analysis

North America represents a developed regional market for organ transplant immunosuppressant drugs. The presence of favorable reimbursement policies, the presence of developed healthcare facilities, technological advancements, and increasing healthcare spending are major factors driving the market growth in this region. Europe was the second largest market in 2023. Asia Pacific is projected to witness rapid CAGR for the organ transplant immunosuppressant drugs market. A dense population base, increasing chronic disease burden, increasing healthcare expenditure, and introduction of favorable reimbursement policies are expected to boost market growth in the Asia Pacific. Latin America is will register noticeable growth over the forecast period. The Middle East and Africa will register sluggish growth in the years to come as a result of a lack of advanced healthcare infrastructure.

Global Organ Transplant Immunosuppressant Drugs Market: Competitive Players

• Bristol-Myers Squibb Company
• Veloxis Pharmaceuticals A/S
• GlaxoSmithKline plc
• Dr. Reddy’s Laboratories Ltd.
• F. Hoffmann-La Roche Ltd.
• Mylan Laboratories
• Novartis AG
• Accord Healthcare Ltd.
• Sanofi Genzyme
• Astellas Pharma

The Global Organ Transplant Immunosuppressant Drugs Market is segmented as follows:

Global Organ Transplant Immunosuppressant Drugs Market: By Drug Class

• Calcineurin Inhibitors
• Antiproliferative Agents
• mTOR Inhibitor
• Steroids
• Antibodies

Global Organ Transplant Immunosuppressant Drugs Market: By Transplant Type

• Kidney
• Liver
• Heart
• Lung
• Pancreas
• Other

Global Organ Transplant Immunosuppressant Drugs Market: By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Organ Transplant Immunosuppressant Drugs Market: By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of The Middle East & Africa